Guardant Health Stock Price, News & Analysis

Guardant Health (Nasdaq: GH) announced publication in the Journal of Clinical Oncology of the largest study to date evaluating ctDNA for molecular residual disease (MRD) in resected stage III colon cancer.

In a phase III cohort of >2,000 patients, Guardant Reveal detected ctDNA in ~20% post-surgery and identified a four‑to‑six‑fold higher risk of recurrence or reduced survival versus standard staging; tumor fraction further stratified highest‑risk patients.

Guardant Health (Nasdaq: GH) will report fourth quarter and full year 2025 financial results after market close on Thursday, February 19, 2026. Management will host a webcast and conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Live audio and archived replay will be available on the company’s Investors website.

Guardant Health (NASDAQ: GH) announced FDA approval of Guardant360 CDx as a companion diagnostic to identify BRAF V600E-mutant metastatic colorectal cancer (mCRC) patients eligible for BRAFTOVI (encorafenib) plus cetuximab and chemotherapy, supported by Pfizer’s Phase 3 BREAKWATER trial.

The approval expands Guardant360 CDx’s role across solid tumors as the platform’s 25th companion diagnostic indication, enables non-invasive ctDNA testing for rapid treatment selection and resistance monitoring, and complements existing Medicare and commercial coverage representing >300 million covered lives.

Guardant Health (Nasdaq: GH) announced a multi-year global collaboration with Merck (MSD outside US/Canada) to use the Guardant Infinity Smart platform across Merck’s oncology programs.

The agreement names Guardant’s liquid and tissue biopsy tests as clinical-trial enrolling assays, contemplates development of novel therapies using Guardant liquid biopsy tests as companion diagnostics, and includes partnering for global commercialization in the US, Asia-Pacific, UK, and EU.

Guardant Health (Nasdaq: GH) reported preliminary, unaudited results for Q4 and full-year 2025, with Q4 revenue of ~$280M (+39% YoY) and FY2025 revenue of ~$981M (+33% YoY). Test volumes rose sharply: ~79,000 oncology tests in Q4 (+38% YoY) and ~276,000 oncology tests for FY2025 (+34% YoY). Shield screening volumes reached ~38,000 in Q4 and ~87,000 for FY2025, with nearly 100,000 patients screened since FDA approval. Preliminary free cash flow was negative ~$54M in Q4 and negative ~$233M for FY2025. Cash and marketable securities totaled ~$1.3B at year-end. Results are unaudited and subject to change; audited results expected on the February 2026 earnings call.

Guardant Health (Nasdaq: GH) announced on January 8, 2026 that its Shield blood test for colorectal cancer screening is now covered by TRICARE for active-duty service members and eligible family members with no copay for average-risk individuals ages 45 and older. Shield is the first and only blood test approved by the FDA as a primary screening option for colorectal cancer and is already covered by Medicare and the Veterans Affairs Community Care Network. The Department of Defense reports about 1.3 million active-duty service members who, along with their screening-eligible family members, gain access to a blood-based alternative to traditional screening. Colorectal cancer has a 91% five-year survival rate when detected early.

Guardant Health (Nasdaq: GH) will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.

Management is scheduled to present and take part in a Q&A on Monday, January 12, 2026 at 3:45 p.m. PT / 6:45 p.m. ET. Live and archived webcasts will be available in the company Investors section at www.guardanthealth.com.

Guardant Health (Nasdaq: GH) announced a strategic collaboration with Trial Library on December 11, 2025 to expand access to oncology clinical trials across the U.S. The partnership pairs Guardant’s real-world genomic dataset of more than 1 million patients tested with Trial Library’s AI matching and navigation platform active in 320+ clinics and with 1,500 providers. The collaboration aims to streamline identification, referral, remote eligibility verification and longitudinal navigation to boost enrollment among representative and underserved populations.

Key figures cited include >70% of patients open to trials versus <7% enrolled, highlighting the access gap the partners seek to address.

Guardant Health (Nasdaq: GH) announced on December 9, 2025 the launch of FPG 360, an in-house liquid biopsy testing service at Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy. The facility will offer on-site testing based on Guardant360 CDx technology to support routine care and clinical research.

The collaboration is described as one of the first dedicated hospital-based liquid biopsy facilities in Italy and follows Guardant Health partnerships with Val d’Hebron/VHIO and The Royal Marsden. The release notes Italy records approximately 400,000 new malignant tumor cases annually and also references Guardant360 CDx certification under EU IVDR obtained last year.